As in the heart and other parts of our bodies, the arteries in our brains become narrowed and finally blocked with plaque, this is called Intracranial Atherosclerosis (ICAD). 10-50% of strokes are caused by ICAD for which current treatment options are sub-optimal, leaving this large population of patients with the ongoing risk of devastating strokes. The Ceroflo SubMaxTM Stent represents a game-changer in the treatment of ICAD as its shape and structure has been developed to suit the unique challenges of this disease. It is designed to gently increase vital blood flow to the brain while reducing the risks associated with first-generation devices, including haemorrhage and stroke. Ceroflo, brings together a stellar team from the Irish medical device industry including the founder and some of the senior leadership team from Neuravi, a company acquired in 2017 by Johnson and Johnson (J&J) in one of the biggest ever MedTech acquisitions in Europe. Ceroflo co-founder Eamon Brady founded Neuravi alongside John O’Shaughnessy and they serve as Chairman and Advisor of Ceroflo respectively. Ceroflo’s CEO Chloe Brown was previously Neuravi’s commercial leader and Ceroflo’s CTO is Brendan Casey, formerly R&D Senior Manager at Neuravi.
Recent Milestones: Closed Pre-Series A round of €6.4M in December 2023 and kicked off €3.4M Disruptive Technology Innovation Fund (Enterprise Ireland) project. ·
Upcoming Milestones: Design Freeze and First in Human study for the SubMax stent.
Products: SubMax Stent for the treatment of Intracranial Atherosclerotic Disease (ICAD)
Investors: Irish Entrepreneurs & Investors.
Full Company address & contact details: Ceroflo Limited, Galway Business Park, Dangan, Galway Ireland H91 P2DK